GlassScriptPhysician profile
Javier V Davis
NPI 1841907714
$2,288.38
in general payments reported to CMS, 2019-2025
15 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $216 · 2024: $938 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $341.12 | 2024-2025 | Austedo Xr, Austedo Xr |
| Braeburn INC. | $313.55 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $249.99 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $246.91 | 2024-2025 | Auvelity |
| Amgen INC. | $148.31 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $122.56 | 2024 | |
| Scpharmaceuticals INC. | $121.89 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Evkeeza |
| Otsuka America Pharmaceutical, INC. | $121.82 | 2025 | Rexulti |
| Novo Nordisk INC | $121.81 | 2025 | |
| Abbvie INC. | $118.15 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.20 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $97.50 | 2023 | Quviviq |
| Indivior INC. | $33.68 | 2024 | Sublocade |
| Uswm, LLC | $20.05 | 2024 | Lucemyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.